Recursion Pharmaceuticals, Inc. proof-of-concept data, from the phase 2 SYCAMORE study using REC-994 for the treatment of patients with Cerebral Cavernous Malformation, expected in the 2nd half of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback